Literature DB >> 15525359

Rabies in red foxes (Vulpes vulpes) experimentally infected with European bat lyssavirus type 1.

A Vos1, T Müller, L Neubert, A Zurbriggen, C Botteron, D Pöhle, H Schoon, L Haas, A C Jackson.   

Abstract

The susceptibility of red foxes (Vulpes vulpes) to European bat lyssavirus type 1 (EBLV-1) infection was examined. Eight foxes were inoculated intramuscularly (i.m.) with 10(4.9) foci-forming units (FFU) (n = 4) and 10(5.1) FFU (n = 4) and observed for up to 90 days. All foxes showed manifestations of a neurologic disorder (e.g. seizures, myoclonus, agitation), starting as early as 5 days post-infection (p.i.). Subsequently, all animals showed improvement followed by one or more relapses. One fox was killed 3 days after it recovered, 26 days post-infection. Two other foxes were also killed 38 and 54 days post-infection after severe neurologic signs returned. All foxes developed a humoral immune response against EBLV-1 as determined in serum and brain tissues. However, no rabies virus antigen was detected in the brain, other tissues and secretions examined (e.g. salivary gland, saliva, tonsils, lungs) by using different standard diagnostic techniques [fluorescent antibody test, reverse transcription polymerase chain reaction (RT-PCR), rabies tissue culture inoculation test], with the exception of one fox in which EBLV-1 RNA was detected by RT-PCR in only the spinal cord. Brain tissues showed moderate to severe multifocal, mononuclear encephalomyelitis in the three foxes that were killed during the observation period, although no EBLV-1 virus was detectable in these tissues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15525359     DOI: 10.1111/j.1439-0450.2004.00793.x

Source DB:  PubMed          Journal:  J Vet Med B Infect Dis Vet Public Health        ISSN: 0931-1793


  6 in total

1.  Intergenotypic replacement of lyssavirus matrix proteins demonstrates the role of lyssavirus M proteins in intracellular virus accumulation.

Authors:  Stefan Finke; Harald Granzow; Jose Hurst; Reiko Pollin; Thomas C Mettenleiter
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

2.  Comparative analysis of European bat lyssavirus 1 pathogenicity in the mouse model.

Authors:  Elisa Eggerbauer; Florian Pfaff; Stefan Finke; Dirk Höper; Martin Beer; Thomas C Mettenleiter; Tobias Nolden; Jens-Peter Teifke; Thomas Müller; Conrad M Freuling
Journal:  PLoS Negl Trop Dis       Date:  2017-06-19

3.  A step forward in molecular diagnostics of lyssaviruses--results of a ring trial among European laboratories.

Authors:  Melina Fischer; Kerstin Wernike; Conrad M Freuling; Thomas Müller; Orhan Aylan; Bernard Brochier; Florence Cliquet; Sonia Vázquez-Morón; Peter Hostnik; Anita Huovilainen; Mats Isaksson; Engbert A Kooi; Jean Mooney; Mihai Turcitu; Thomas B Rasmussen; Sandra Revilla-Fernández; Marcin Smreczak; Anthony R Fooks; Denise A Marston; Martin Beer; Bernd Hoffmann
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

4.  Experimental infection of foxes with European Bat Lyssaviruses type-1 and 2.

Authors:  Florence Cliquet; Evelyne Picard-Meyer; Jacques Barrat; Sharon M Brookes; Derek M Healy; Marine Wasniewski; Estelle Litaize; Mélanie Biarnais; Linda Johnson; Anthony R Fooks
Journal:  BMC Vet Res       Date:  2009-05-19       Impact factor: 2.741

5.  Cross-neutralization of antibodies induced by vaccination with Purified Chick Embryo Cell Vaccine (PCECV) against different Lyssavirus species.

Authors:  Claudius Malerczyk; Conrad Freuling; Dieter Gniel; Alexandra Giesen; Thomas Selhorst; Thomas Müller
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Comparative pathogenesis of different phylogroup I bat lyssaviruses in a standardized mouse model.

Authors:  Antonia Klein; Elisa Eggerbauer; Madlin Potratz; Luca M Zaeck; Sten Calvelage; Stefan Finke; Thomas Müller; Conrad M Freuling
Journal:  PLoS Negl Trop Dis       Date:  2022-01-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.